Safety and Efficacy of Satralizumab in Patients with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): Results from the Phase 3 METEOROID Trial (PL5.006)
Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available
10.1212/wnl.0000000000217915